The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains

Victor Ghetie, Andreas Engert, Roland Schnell, Ellen S. Vitetta

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We have compared the in vitro and in vivo activities of three deglycosylated ricin A chain (dgA)-containing immunotoxins (ITs) with one versus two molecules of dgA per molecule of IgG. Two of the ITs (anti-CD19-dgA2 and anti-CD25-dgA2) had 3-0-fold improvements over their dgA1 counterparts in vitro. However, the in vivo anti-tumor activity of both constructs of each IT was the same. In contrast, anti-CD22-dgA2 was 7-fold more potent in vitro and significantly more potent in vivo than its dgA1 counterpart. These studies suggest that monoclonal antibodies must be individually tested to determine whether the addition of two versus one dgA will improve cytotoxic activity in vivo.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalCancer Letters
Volume98
Issue number1
DOIs
StatePublished - Nov 27 1995

Fingerprint

Ricin
Immunotoxins
Neoplasms
Immunoglobulin G
Monoclonal Antibodies
In Vitro Techniques

Keywords

  • CD19
  • CD22
  • CD25
  • Immunotoxin
  • Ricin A chain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Biology

Cite this

The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. / Ghetie, Victor; Engert, Andreas; Schnell, Roland; Vitetta, Ellen S.

In: Cancer Letters, Vol. 98, No. 1, 27.11.1995, p. 97-101.

Research output: Contribution to journalArticle

Ghetie, Victor ; Engert, Andreas ; Schnell, Roland ; Vitetta, Ellen S. / The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. In: Cancer Letters. 1995 ; Vol. 98, No. 1. pp. 97-101.
@article{62eceb6eecc84ae6a8abc99b783f30ad,
title = "The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains",
abstract = "We have compared the in vitro and in vivo activities of three deglycosylated ricin A chain (dgA)-containing immunotoxins (ITs) with one versus two molecules of dgA per molecule of IgG. Two of the ITs (anti-CD19-dgA2 and anti-CD25-dgA2) had 3-0-fold improvements over their dgA1 counterparts in vitro. However, the in vivo anti-tumor activity of both constructs of each IT was the same. In contrast, anti-CD22-dgA2 was 7-fold more potent in vitro and significantly more potent in vivo than its dgA1 counterpart. These studies suggest that monoclonal antibodies must be individually tested to determine whether the addition of two versus one dgA will improve cytotoxic activity in vivo.",
keywords = "CD19, CD22, CD25, Immunotoxin, Ricin A chain",
author = "Victor Ghetie and Andreas Engert and Roland Schnell and Vitetta, {Ellen S.}",
year = "1995",
month = "11",
day = "27",
doi = "10.1016/S0304-3835(06)80016-9",
language = "English (US)",
volume = "98",
pages = "97--101",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains

AU - Ghetie, Victor

AU - Engert, Andreas

AU - Schnell, Roland

AU - Vitetta, Ellen S.

PY - 1995/11/27

Y1 - 1995/11/27

N2 - We have compared the in vitro and in vivo activities of three deglycosylated ricin A chain (dgA)-containing immunotoxins (ITs) with one versus two molecules of dgA per molecule of IgG. Two of the ITs (anti-CD19-dgA2 and anti-CD25-dgA2) had 3-0-fold improvements over their dgA1 counterparts in vitro. However, the in vivo anti-tumor activity of both constructs of each IT was the same. In contrast, anti-CD22-dgA2 was 7-fold more potent in vitro and significantly more potent in vivo than its dgA1 counterpart. These studies suggest that monoclonal antibodies must be individually tested to determine whether the addition of two versus one dgA will improve cytotoxic activity in vivo.

AB - We have compared the in vitro and in vivo activities of three deglycosylated ricin A chain (dgA)-containing immunotoxins (ITs) with one versus two molecules of dgA per molecule of IgG. Two of the ITs (anti-CD19-dgA2 and anti-CD25-dgA2) had 3-0-fold improvements over their dgA1 counterparts in vitro. However, the in vivo anti-tumor activity of both constructs of each IT was the same. In contrast, anti-CD22-dgA2 was 7-fold more potent in vitro and significantly more potent in vivo than its dgA1 counterpart. These studies suggest that monoclonal antibodies must be individually tested to determine whether the addition of two versus one dgA will improve cytotoxic activity in vivo.

KW - CD19

KW - CD22

KW - CD25

KW - Immunotoxin

KW - Ricin A chain

UR - http://www.scopus.com/inward/record.url?scp=0028815604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028815604&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(06)80016-9

DO - 10.1016/S0304-3835(06)80016-9

M3 - Article

C2 - 8529213

AN - SCOPUS:0028815604

VL - 98

SP - 97

EP - 101

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -